Cite
MLA Citation
Mark A Chilvers et al.. “Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.” Lancet, vol. 9, no. 7, 2021, pp. 721–732. http://access.bl.uk/ark:/81055/vdc_100133916104.0x00000e